Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.The Company is dedicated to developing and bringing to market therapies that target each class of molecular pathways regulating apoptosis, or programmed cell death, in a wide range of indications. Headquartered in Suzhou, China, we are a rapidly growing company with offices in three countries.Ascentage Pharma has built a pipeline of seven clinical drug candidates, including novel, highly selective and potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, additional apoptotis inhibitors targeting IAP and MDM2-p53 proteins. The pipeline is balanced by next-generation tyrosine kinase inhibitors (TKIs) aimed at treatment induced resistance mutations. Ascentage Pharma is conducting more than 40 clinical trials in specific regions worldwide.